Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

Cited by (875)

Items 201–300 of 875

1. Monitoring multiple myeloma by quantification of recurrent mutations in serum
   Even Holth Rustad, Eivind Coward, Emilie Ranheim Skytøen, Kristine Misund, Toril Holien, Therese Standal, Magne Børset, Vidar Beisvåg, Ola Myklebost, Leonardo A. Meza‐Zepeda et al. · 2017 · Haematologica
2. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
   Niccolò Bolli, Elisa Genuardi, Bachisio Ziccheddu, Marina Martello, Stefania Oliva, Carolina Terragna · 2020 · Frontiers in Oncology
3. Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
   Ioannis V. Kostopoulos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Ourania Tsitsilonis, Evangelos Terpos · 2020 · Frontiers in Oncology
4. A recurrent novel MGA–NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma
   Daniel Diolaiti, Filemon S. Dela Cruz, Gunes Gundem, Nancy Bouvier, Mathieu Boulad, Yanming Zhang, Alexander J. Chou, Ira J. Dunkel, Rashesh Sanghvi, Minita J. Shah et al. · 2018 · Molecular Case Studies
5. The mutagenic impact of melphalan in multiple myeloma
   Francesco Maura, Niels Weinhold, Benjamin T. Diamond, Dickran Gano Kazandjian, Leo Rasche, Gareth John Morgan, Ola Landgren · 2021 · Leukemia
6. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
   Kristine Misund, Davine Hofste op Bruinink, Eivind Coward, Remco Michiel Hoogenboezem, Even Holth Rustad, Mathijs Arnoud Sanders, Morten Beck Rye, Anne‐Marit Sponaas, Bronno van der Holt, Sonja Zweegman et al. · 2022 · Leukemia
7. *K-means and cluster models for cancer signatures
   Zura Kakushadze, Willie Yu · 2017 · Biomolecular Detection and Quantification
8. Deciphering the chronology of copy number alterations in Multiple Myeloma
   Anıl Aktaş Samur, Stéphane Minvielle, Masood A. Shammas, Mariateresa Fulciniti, Florence Magrangeas, Paul Gerard Guy Richardson, Philippe Moreau, Michel Attal, Kenneth Carl Anderson, Giovanni Parmigiani et al. · 2019 · Blood Cancer Journal
9. Molecular basis of clonal evolution in multiple myeloma
   Yusuke Furukawa, Jiro Kikuchi · 2020 · International Journal of Hematology
10. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
    Kari Hemminki, Asta Försti, Richard S. Houlston, Amit Sud · 2021 · International Journal of Cancer
11. How to Treat High-Risk Myeloma at Diagnosis and Relapse
    Jessica Caro, Samer Al Hadidi, Saad Z. Usmani, Andrew Jenho Yee, Noopur S Raje, Faith E. Davies · 2021 · American Society of Clinical Oncology Educational Book
12. Single-molecule analysis reveals widespread structural variation in multiple myeloma
    Aditya Gupta, Michael Place, Steven Goldstein, Deepayan Sarkar, Shiguo Zhou, Konstantinos D. Potamousis, Jaehyup Kim, Claire E. Flanagan, Yang Li, Michael A. Newton et al. · 2015 · Proceedings of the National Academy of Sciences
13. Advances in the pathogenesis and diagnosis of multiple myeloma
    Marta Chesi, Peter Leif Bergsagel · 2015 · International Journal of Laboratory Hematology
14. Differential and limited expression of mutant alleles in multiple myeloma
    Naim U. Rashid, Adam Samuel Sperling, Niccolò Bolli, David C. Wedge, Peter Van Loo, Yu‐Tzu Tai, Masood A. Shammas, Mariateresa Fulciniti, Mehmet Samur, Paul Gerard Guy Richardson et al. · 2014 · Blood
15. Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition
    Marc Steffen Raab, Nicola Lehners, Jing Xu, Anthony Dick Ho, Peter Schirmacher, Hartmut Goldschmidt, Mindaugas Andrulis · 2016 · Blood
16. Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma
    Ehsan Malek, M A Y Abdel-Malek, Sajjeev Jagannathan, Nikhil M. Vad, Rebekah A. Karns, Anil Goud Jegga, Annemiek Broyl, Mark van Duin, Pieter Sonneveld, Francesca Cottini et al. · 2016 · Leukemia
17. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
    Klaus Martin Kortuem, Esteban Braggio, Laura Ann Bruins, Santiago Barrio, Chenlai Shi, Ya-Jie Zhu, Raoul Tibes, David S. Viswanatha, Patrick G. Votruba, Gregory J. Ahmann et al. · 2016 · Blood Cancer Journal
18. Re-Evaluating Clonal Dominance in Cancer Evolution
    Rebecca A. Burrell, Charles Swanton · 2016 · Trends in cancer
19. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
    Charlotte Pawlyn, Andrea Loehr, Cody Ashby, Ruslana G. Tytarenko, Shayu Deshpande, James X. Sun, Kyle Fedorchak, Tariq I. Mughal, Faith E. Davies, Brian A. Walker et al. · 2018 · Leukemia
20. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
    Taylor Harding, Linda Banovic Baughn, Shaji Kunnathu Kumar, Brian Van Ness · 2019 · Leukemia
21. FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy
    Nicola Manfrini, Marilena Mancino, Annarita Miluzio, Stefania Oliveto, Matteo Balestra, Piera Calamita, Roberta R Alfieri, Riccardo Lorenzo Rossi, Marco Sassoé‐Pognetto, Chiara Salio et al. · 2020 · Cancer Research
22. Cereblon binding molecules in multiple myeloma
    Klaus Martin Kortüm, Yuan Xiao Zhu, Chao Shi, Patrick Michael Jedlowski, A. Keith Stewart · 2015 · Blood Reviews
23. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
    Teru Hideshima, Francesca Cottini, Yoshihisa Nozawa, Hyuk‐Soo Seo, Hiroto Ohguchi, Mehmet Samur, Diana D. Cirstea, Naoya Mimura, Yoshikazu Iwasawa, Paul Gerard Guy Richardson et al. · 2017 · Blood
24. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development
    Kevin Dzobo, Dimakatso Alice Senthebane, Nicholas Ekow Thomford, Arielle Rowe, Collet Dandara, Mohamed Iqbal Parker · 2018 · OMICS A Journal of Integrative Biology
25. Mutational processes contributing to the development of multiple myeloma
    Phuc H. Hoang, Alex J. Cornish, Sara E. Dobbins, Martin Kaiser, Richard S. Houlston · 2019 · Blood Cancer Journal
26. Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol
    Niccolò Bolli, Nicla Manes, Thomas McKerrell, J. Chi, N. Park, Gunes Gundem, Michael Andrew Quail, Vijitha Sathiaseelan, Bram Herman, Charles R. Crawley et al. · 2014 · Haematologica
27. Inferring mutational timing and reconstructing tumour evolutionary histories
    Samra Turajlic, Nicholas McGranahan, Charles Swanton · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
28. How I treat smoldering multiple myeloma
    Irene M. Ghobrial, Ola Landgren · 2014 · Blood
29. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome
    Francesco Favero, Nicholas McGranahan, Maximilian P Salm, Nicolai J. Birkbak, Zack Sanborn, Stephen Charles Benz, Jennifer Becq, John F. Peden, Zoya Kingsbury, Russell Grocock et al. · 2015 · Annals of Oncology
30. Genomic Instability in Multiple Myeloma
    David A. Alagpulinsa, Raphael Elie Szalat, Mark C. Poznansky, Robert J. Shmookler Reis · 2020 · Trends in cancer
31. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M3P)
    Klaus Martin Kortüm, Christian Langer, Jorge Monge, Laura Ann Bruins, Yuan Xiao Zhu, C. X. Shi, Patrick Michael Jedlowski, Jan B. Egan, Juhi Ojha, Lars Bullinger et al. · 2015 · Annals of Hematology
32. FastClone is a probabilistic tool for deconvoluting tumor heterogeneity in bulk-sequencing samples
    Yao Xiao, Xueqing Wang, Hongjiu Zhang, Peter Ulintz, Hongyang Li, Yuanfang Guan · 2020 · Nature Communications
33. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
    on behalf of the GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group, Juan‐José Garcés, Gabriel Bretones, Leire Burgos, Rafael Valdés‐Mas, Noemí Puig, María‐Teresa Cedena, Diego Alignani, Idoia Rodríguez, Diana Álvarez Puente et al. · 2020 · Leukemia
34. Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
    Arif E. Çetin, Mark M. Stevens, Nicholas L. Calistri, Mariateresa Fulciniti, Selim Olçum, Robert J. Kimmerling, Nikhil C. Munshi, Scott R. Manalis · 2017 · Nature Communications
35. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma
    Francesco Maura, Niccolò Bolli, Even Holth Rustad, Malin L. Hultcrantz, Nikhil C. Munshi, Ola Landgren · 2019 · JAMA Oncology
36. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
    Eileen Mary Boyle, Cody Ashby, Ruslana G. Tytarenko, Shayu Deshpande, Hongwei Wang, Yan Wang, Adam Rosenthal, Jeffrey R. Sawyer, Erming Tian, Erin Flynt et al. · 2020 · Clinical Cancer Research
37. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
    Fabian Frontzek, Annette M. Staiger, Myroslav Zapukhlyak, Wendan Xu, Irina Bonzheim, Vanessa Borgmann, Philip Sander, Maria João Baptista, Jan-Niklas Heming, Philipp Berning et al. · 2021 · Nature Communications
38. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
    Lukas John, Alexandra Maria Poos, Alexander Brobeil, Carolina Schinke, Stefanie Huhn, Nina Prokoph, Raphael Lutz, Barbara Wagner, Maurizio Zangari, Stephan M. Tirier et al. · 2023 · Nature Communications
39. The long-term effects of chemotherapy on normal blood cells
    Emily Mitchell, My H. Pham, Anna Clay, Rashesh Sanghvi, Nicholas Williams, Sandra Pietsch, Joanne I. Hsu, Nina Friesgaard Øbro, Hyunchul Jung, Aditi Vedi et al. · 2025 · Nature Genetics
40. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias
    Marta Lionetti, Marzia Barbieri, Katia Todoerti, Luca Agnelli, Sonia Fabris, Giovanni Tonon, Simona Segalla, Ingrid Cifola, Eva Pinatel, Pierfrancesco Tassone et al. · 2015 · Oncotarget
41. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
    Dickran Gano Kazandjian, Elizabeth Hill, Malin L. Hultcrantz, Even Holth Rustad, Venkata D. Yellapantula, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alex Dew, Elli Papaemmanuil et al. · 2019 · Blood Cancer Journal
42. Kinome expression profiling to target new therapeutic avenues in multiple myeloma
    Hugues de Boussac, Angélique Bruyer, Michel Jourdan, Anke Maes, Nicolas Robert, Claire Gourzonès, Laure Vincent, Anja Seckinger, Guillaume Cartron, Dirk Hose et al. · 2019 · Haematologica
43. Differential expression of neurogenes among breast cancer subtypes identifies high risk patients
    Patricia Fernández‐Nogueira, Paloma Bragado, Vanessa Almendro, Elisabet Ametller, José Ríos, Sibgat A. Choudhury, Mario Mancino, Pedro Gascón · 2015 · Oncotarget
44. The possible role of burden of therapy on the risk of myeloma extramedullary spread
    Silvia Mangiacavalli, Alessandra Pompa, Virginia Valeria Ferretti, Catherine Klersy, Federica Cocito, Marzia Varettoni, Claudio Salvatore Cartia, Mario Cazzola, Alessandro Corso · 2016 · Annals of Hematology
45. Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance
    Subodh Kumar, Srikanth Talluri, Jagannath Pal, Xiaoli Yuan, Renquan Lu, Puru Nanjappa, Mehmet Samur, Nikhil C. Munshi, Masood A. Shammas · 2018 · Blood Cancer Journal
46. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
    Maroulio Pertesi, Maxime Vallée, Xiaomu Wei, Maria Victoria Revuelta, Perrine Galia, Delphine Demangel, Javier Oliver, Matthieu Foll, Siwei Chen, Emeline Cros‐Perrial et al. · 2019 · Leukemia
47. Chimeric antigen receptor T cell therapies for multiple myeloma
    Chao Wu, Lina Zhang, Qierra R. Brockman, Fenghuang Zhan, Lijuan Chen · 2019 · Journal of Hematology & Oncology
48. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma
    José Alberto Nakauma‐González, Maud Rijnders, Job van Riet, Michiel S. van der Heijden, Jens Voortman, Edwin P. J. G. Cuppen, Niven Mehra, Sandra van Wilpe, Sjoukje F. Oosting, L. Lucia Rijstenberg et al. · 2022 · European Urology
49. NF-κB dysregulation in multiple myeloma
    Geoffrey M. Matthews, Ricardo De Matos Simoes, Eugen Dhimolea, Michal Sheffer, Sara Gandolfi, Olga Dashevsky, Jeffrey Sorrell, Constantine S. Mitsiades · 2016 · Seminars in Cancer Biology
50. High expression of UBE2T predicts poor prognosis and survival in multiple myeloma
    Weilong Zhang, Y. Zhang, Zuozhen Yang, Xiaoni Liu, Ping Yang, Jing Wang, Kai Hu, Xue He, Xiuru Zhang, Hongmei Jing · 2019 · Cancer Gene Therapy
51. Hypermutation in single-stranded DNA
    Natalie Saini, Dmitry A. Gordenin · 2020 · DNA repair
52. Krüppel-Like Factor 12 Promotes Colorectal Cancer Growth through Early Growth Response Protein 1
    Sun-Hee Kim, Yun‐Yong Park, Sung-Nam Cho, Ofer Margalit, Dingzhi Wang, Raymond N. DuBois · 2016 · PLoS ONE
53. Expressed fusion gene landscape and its impact in multiple myeloma
    Alice Cleynen, Raphael Elie Szalat, Mehmet Samur, Sébastien Robiou-du-Pont, Laure Buisson, Eileen Mary Boyle, Marie‐Lorraine Chrétien, Kenneth Carl Anderson, Stéphane Minvielle, Philippe Moreau et al. · 2017 · Nature Communications
54. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
    Angélique Bruyer, Ken Maes, Laurie Herviou, Alboukadel Kassambara, Anja Seckinger, Guillaume Cartron, Thierry X. Reme, Nicolas Robert, Guilhem Requirand, Stéphanie Boireau et al. · 2018 · British Journal of Cancer
55. The biological significance of histone modifiers in multiple myeloma: clinical applications
    Hiroto Ohguchi, Teru Hideshima, Kenneth Carl Anderson · 2018 · Blood Cancer Journal
56. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
    Laurie Herviou, Alboukadel Kassambara, Stéphanie Boireau, Nicolas Robert, Guilhem Requirand, Carsten Müller‐Tidow, Laure Vincent, Anja Seckinger, Hartmut Goldschmidt, Guillaume Cartron et al. · 2018 · Clinical Epigenetics
57. The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies
    Rafael Colmenares, Noemi De Dios Alvarez, Santiago Barrio, Joaquín Martínez‐López, Rosa María Ayala · 2022 · Cancers
58. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature
    Marta Lionetti, Marzia Barbieri, Martina Manzoni, Sonia Fabris, Cecilia Bandini, Katia Todoerti, Filomena Nozza, Davide Rossi, Pellegrino Musto, Luca Baldini et al. · 2016 · Oncotarget
59. A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma
    Domenica Ronchetti, Luca Agnelli, Alessandro Pietrelli, Katia Todoerti, Martina Manzoni, Elisa Taìana, Antonino Neri · 2018 · Scientific Reports
60. Progress in the identification of gene mutations involved in multiple myeloma
    Ying Hu, Wen-Ming Chen, Jingbo Wang · 2019 · OncoTargets and Therapy
61. Compendium of FAM 46C gene mutations in plasma cell dyscrasias
    Marzia Barbieri, Martina Manzoni, Sonia Fabris, Gabriella Ciceri, Katia Todoerti, Vittorio Simeon, Pellegrino Musto, Agostino Cortelezzi, Luca Baldini, Antonino Neri et al. · 2015 · British Journal of Haematology
62. SnapShot: Multiple Myeloma
    Esteban Braggio, Klaus Martin Kortüm, A. Keith Stewart · 2015 · Cancer Cell
63. A functional variant that affects exon-skipping and protein expression ofSP140as genetic mechanism predisposing to multiple sclerosis
    Fuencisla Matesanz, Víctor Potenciano, Marı́a Fedetz, Priscila Ramos‐Mozo, María M. Abad‐Grau, Mohamad Karaky, Cristina Barrionuevo, Guillermo Izquierdo, Juan Luis Ruíz-Peña, Maria-Isabel García-Sanchéz et al. · 2015 · Human Molecular Genetics
64. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
    Erik H. van Beers, Martin H. van Vliet, Rowan Kuiper, Leonie de Best, Kenneth Carl Anderson, Ajai Chari, Sundar Jagannath, Andrzej J. Jakubowiak, Shaji Kunnathu Kumar, Joan B. Levy et al. · 2017 · Clinical Lymphoma Myeloma & Leukemia
65. The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?
    Alexander Höllein, Sven Olaf Twardziok, Wencke Walter, Stephan Hütter, Constance Regina Baer, Jesús María Hernández-Sánchez, Manja Meggendorfer, Torsten Haferlach, Wolfgang Kern, Claudia Haferlach · 2020 · Cancer Genetics
66. Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
    Kerstin Thol, Piotr Pawlik, Nicholas McGranahan · 2022 · Genome Medicine
67. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
    Faith E. Davies, Charlotte Pawlyn, Saad Z. Usmani, Jesús F. San Miguel, Hermann Einsele, Eileen Mary Boyle, Jill Corre, Daniel Auclair, Hearn Jay Cho, Sagar Lonial et al. · 2022 · Blood Cancer Discovery
68. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in ‐17p high risk disease
    Klaus Martin Kortüm, Christian Langer, Jorge Monge, Laura Ann Bruins, Jan B. Egan, Yuan Xiao Zhu, Shi Chang, Patrick Michael Jedlowski, Jessica E. Schmidt, Juhi Ojha et al. · 2014 · British Journal of Haematology
69. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma
    Salomon Manier, Yawara Kawano, Giada Bianchi, Aldo Maria Roccaro, Irene M. Ghobrial · 2016 · Current Opinion in Hematology
70. Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
    Muntasir Mamun Majumder, Raija Helena Silvennoinen, Pekka M. Anttila, David Tamborero, Samuli Eldfors, Bhagwan Yadav, Riikka Karjalainen, Heikki A Kuusanmäki, Juha Lievonen, Alun Parsons et al. · 2017 · Oncotarget
71. From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation
    Cristina Jiménez, Sara Alonso, Miguel Alcoceba, Gonzalo R. Ordóñez, María García‐Álvarez, Isabel Prieto-Conde, Carmen Chillón, Ana Balanzategui, Rocío Corral, Luis Marı́n et al. · 2017 · Blood Cancer Journal
72. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
    Sham Mailankody, Dickran Gano Kazandjian, Neha Korde, Mark J. Roschewski, Elisabet Esteve Manasanch, Manisha Bhutani, Nishant Tageja, Mary Kwok, Yong Zhang, Adriana Zingone et al. · 2017 · Blood Advances
73. The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation
    Fabrice Chatonnet, Amandine Pignarre, Aurélien A. Sérandour, Gersende Caron, Stéphane Avner, Nicolas Robert, Alboukadel Kassambara, Audrey Laurent, Maud Bizot, Xabier Agirre et al. · 2019 · Haematologica
74. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
    Carolina Schinke, Eileen Mary Boyle, Cody Ashby, Yan Wang, Valeriy V. Lyzogubov, Christopher P. Wardell, Pingping Qu, Antje Hoering, Shayu Deshpande, Katie Rose Ryan et al. · 2020 · Blood Cancer Journal
75. AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma
    Timon A. Bloedjes, Guus de Wilde, Chiel Maas, Eric Eldering, Richard J. Bende, Carel J.M. van Noesel, Steven T. Pals, Marcel Spaargaren, Jeroen E. J. Guikema · 2020 · Blood Advances
76. Multiple Myeloma: Heterogeneous in Every Way
    Anaïs Schavgoulidze, Titouan Cazaubiel, Aurore Perrot, Hervé Avet‐Loiseau, Jill Corre · 2021 · Cancers
77. Molecular and immunological mechanisms of clonal evolution in multiple myeloma
    Stefan Forster, Ramin Radpour, Adrian F. Ochsenbein · 2023 · Frontiers in Immunology
78. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias
    Bernhard Gerber, Martina Manzoni, Valeria Spina, Alessio Bruscaggin, Marta Lionetti, Sonia Fabris, Marzia Barbieri, Gabriella Ciceri, Alessandra Pompa, Gabriela Forestieri et al. · 2018 · Haematologica
79. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations
    Romain Lannes, Mehmet Samur, Aurore Perrot, Céline Mazzotti, Marion Divoux, Titouan Cazaubiel, Xavier P Leleu, Anaïs Schavgoulidze, Marie‐Lorraine Chrétien, Salomon Manier et al. · 2022 · Journal of Clinical Oncology
80. MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology
    Dutta, Ankit K., Alberge, Jean-Baptiste, Lightbody, Elizabeth D., Boehner, Cody J., Dunford, Andrew, Sklavenitis-Pistofidis, Romanos, Mouhieddine, Tarek H., Cowan, Annie N., Su, Nang Kham, Horowitz, Erica M. et al. · 2023 · Cancer Discovery
81. The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion
    Anna Burford, Alan G. Mackay, Sergey Popov, Maria Vinci, Diana M. Carvalho, Matthew Clarke, Elisa Izquierdo, Aimee Avery, Thomas S. Jacques, Wendy J. Ingram et al. · 2018 · Scientific Reports
82. Experimental Evolution of Extreme Resistance to Ionizing Radiation in Escherichia coli after 50 Cycles of Selection
    Steven T. Bruckbauer, Joseph D. Trimarco, Joel Martin, Brian Bushnell, Katherine A Senn, Wendy Schackwitz, Anna Lipzen, Matthew J. Blow, Elizabeth A. Wood, Wesley S. Culberson et al. · 2019 · Journal of Bacteriology
83. Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression
    Alissa Visram, Surendra Dasari, Emilie Anderson, Shaji Kunnathu Kumar, Taxiarchis Kourelis · 2021 · Blood Cancer Journal
84. Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
    Naser Ansari‐Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, María Ortiz Estévez, Konstantinos Mavrommatis, Brian A. Walker, Gareth John Morgan et al. · 2022 · Blood
85. Clonal origin and spread of metastatic prostate cancer
    Jamie L. Van Etten, Scott M. Dehm · 2016 · Endocrine Related Cancer
86. Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
    Sridurga Mithraprabhu, Shreerang Sirdesai, Maoshan Chen, Tiffany T. Khong, Andrew G Spencer · 2018 · International Journal of Molecular Sciences
87. Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-Up and Cytogenetic Subgroup Analysis
    on behalf of Deutsche Studiengruppe Multiples Myelom, Stefan Tobias Knop, Monika Martha Engelhardt, Peter Liebisch, Christoph Meisner, Ernst Holler, Bernd Metzner, D. Peest, Martin Kaufmann, Donald Werner Bunjes et al. · 2019 · Leukemia
88. Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma
    Srikanth Talluri, Mehmet Samur, Leutz Buon, Subodh Kumar, Lakshmi B. Potluri, Jialan Shi, RAO H. PRABHALA, Masood A. Shammas, Nikhil C. Munshi · 2021 · Blood Cancer Journal
89. Genome Instability in Multiple Myeloma: Facts and Factors
    Anna Yu. Aksenova, Anna S. Zhuk, Artem G. Lada, Irina V. Zotova, Elena Igorevna Stepchenkova, Ivan Ivanovich Kostroma, Sergey V. Gritsaev, Youri I. Pavlov · 2021 · Cancers
90. YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis
    Zhen Hua, Rongfang Wei, Mengjie Guo, Zigen Lin, Xichao Yu, Xinying Li, Chunyan Gu, Ye Yang · 2022 · Oncogene
91. Polyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders
    Stefan Mittermayr, Giao N Le, Colin Clarke, Silvia Millán‐Martín, Annemarie Larkin, Peter O’Gorman, Jonathan Bones · 2016 · Journal of Proteome Research
92. Chromothripsis as a pathogenic driver of multiple myeloma
    Francesco Maura, Eileen Mary Boyle, Even Holth Rustad, Cody Ashby, David Kaminetzky, Benedetto Bruno, Marc Justin Braunstein, Michael Bauer, Patrick Blaney, Yubao Wang et al. · 2021 · Seminars in Cell and Developmental Biology
93. De novo mutational signature discovery in tumor genomes using SparseSignatures
    Avantika Lal, Keli Liu, Robert John Tibshirani, Arend Sidow, Daniele Ramazzotti · 2021 · PLoS Computational Biology
94. Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming
    Yuanzheng Liang, Haiyan He, Weida Wang, Henan Wang, Shaowen Mo, Ruiying Fu, Xindi Liu, Qiong Song, Zhongjun Xia, Liang Wang · 2022 · Molecular Cancer
95. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
    Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, Tatsushi Kawada, Satoshi Katayama, Kensuke Bekku, Ekaterina Laukhtina, Paweł Rajwa, Fahad Quhal, Benjamin Pradère et al. · 2024 · Cancer Immunology Immunotherapy
96. Genomic heterogeneity in multiple myeloma
    Raphael Elie Szalat, Nikhil C. Munshi · 2015 · Current Opinion in Genetics & Development
97. Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’
    Matthew Ho, Amanda H McCann, Giada Bianchi, Li Zhang, Paul Dowling, Despina Bazou, Peter O’Gorman, Kenneth Carl Anderson · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
98. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma
    Dana Cholujová, Zdenka Lukáčová Bujňáková, Erika Dutková, Teru Hideshima, Richard W.J. Groen, Constantine S. Mitsiades, Paul Gerard Guy Richardson, David M. Dorfman, Peter Baláž, Kenneth Carl Anderson et al. · 2017 · British Journal of Haematology
99. Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
    Alessandro Laganà, Itai Beno, David T. Melnekoff, Violetta V. Leshchenko, Deepu Madduri, Dennis Ramdas, Larysa Jessica Sanchez, Scot Anthony Niglio, Deepak Perumal, Brian A. Kidd et al. · 2018 · JCO Precision Oncology
100. Genetic and transcriptional landscape of plasma cells in POEMS syndrome
     Yuhei Nagao, Naoya Mimura, June Takeda, Kenichi Yoshida, Yusuke Shiozawa, Motohiko Oshima, Kazumasa Aoyama, Atsunori Saraya, Shuhei Koide, Ola Rizq et al. · 2019 · Leukemia